Article

T cell transcriptional and receptor signatures predict response to telomerase vaccination in prostate cancer

2026-05-30

Abstract excerpt

While prostate cancer (PC) is defined as immunologically cold, limiting the efficacy of immune checkpoint inhibitors, therapeutic vaccination targeting tumor-associated antigens represents an attractive strategy to promote disease control in low volume metastatic patients. The UV1 cancer vaccine is based on immunization with tripeptide fragments from human telomerase reverse transcriptase (hTERT) and a phase II cl...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 161a71bd-3e27-5aaa-be02-0e70cff7aa87
DOI: 10.64898/2026.05.25.26354038

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

T cell transcriptional and receptor signatures predict response to telomerase vaccination in prostate cancerDOI 10.64898/2026.05.25.26354038Read

T Cell Receptor repertoire analysis reveals antigenic convergence and immunotherapeutic opportunities in Prostate CancerSemantic proximity Read

PD-1 defines a distinct, functional, tissue-adapted state in Vδ1+ T cells with implications for cancer immunotherapySemantic proximity Read

Nivolumab in Patients with Metastatic Castration-Resistant Prostate Cancer with and without DNA Repair DefectsSemantic proximity Read

Case Report: Targeting of individual somatic tumor mutations by multipeptide vaccination tailored for HLA class I and II presentation induces strong CD4 and CD8 T-cell responses in a patient with metastatic castration sensitive prostate cancer.Semantic proximity Read

Immunotherapy for Prostate Cancer: Treatments for the "Lethal" Phenotype.Semantic proximity Read

BET inhibition sensitizes immunologically-cold Rb-deficient prostate cancer to immune checkpoint blockadeSemantic proximity Read

A Subset of Localized Prostate Cancer Displays an Immunogenic Phenotype Associated with Losses of Key Tumor Suppressor Genes.Semantic proximity Read

The temporal dynamics of the immune response to neoadjuvant androgen deprivation therapy suggests a window-of-opportunity for checkpoint inhibitor therapy in prostate cancerSemantic proximity Read

PSMA-CAR-T Cells for Metastatic Castration-Resistant Prostate Cancer: An Integrated Framework for Translational OptimizationSemantic proximity Read

Androgen Deprivation Therapy Drives a Distinct Immune Phenotype in Localized Prostate Cancer.Semantic proximity Read

Multicenter Phase I Trial of a DNA Vaccine Encoding the Androgen Receptor Ligand-binding Domain (pTVG-AR, MVI-118) in Patients with Metastatic Prostate CancerSemantic proximity Read

DNA vaccines for the treatment of prostate cancerSemantic proximity Read